Cargando…

Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult

OBJECTIVES: Lymphatic malformations (LMs) are aberrant proliferation of sequestrated lymphatic vessels during early embryogenesis and do not communicate directly with the general lymphatic system. The absence of vascular flow is the hallmark of LMs and is usually symptomless apart from painless disf...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatnagar, Ankur, Upadhyaya, Vijai Datta, Kumar, Basant, Neyaz, Zafar, Kushwaha, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773987/
https://www.ncbi.nlm.nih.gov/pubmed/29386816
http://dx.doi.org/10.4103/njms.NJMS_6_17
_version_ 1783293677885456384
author Bhatnagar, Ankur
Upadhyaya, Vijai Datta
Kumar, Basant
Neyaz, Zafar
Kushwaha, Ajay
author_facet Bhatnagar, Ankur
Upadhyaya, Vijai Datta
Kumar, Basant
Neyaz, Zafar
Kushwaha, Ajay
author_sort Bhatnagar, Ankur
collection PubMed
description OBJECTIVES: Lymphatic malformations (LMs) are aberrant proliferation of sequestrated lymphatic vessels during early embryogenesis and do not communicate directly with the general lymphatic system. The absence of vascular flow is the hallmark of LMs and is usually symptomless apart from painless disfiguring mass with concerns regarding cosmesis. DESIGN: Sclerotherapy has gained prominence as a preferred treatment modality for macrocystic lesions. Here, we present our experience with use of aqueous bleomycin as intralesional sclerosing agent, an economical first-line treatment for macrocystic variant of LMs in children and adults. While bleomycin microsphere in oil has been commonly used in many previous studies, we have used aqueous bleomycin solution as the sclerosing modality which is easily available and economical. MATERIALS AND METHODS: Twenty-seven patients of macrocystic LM including adults and children underwent bleomycin sclerotherapy under ultrasonography guidance. Number of sessions, dose administered, and the response to therapy along with all side effects were noted. RESULTS: Sixteen patients received 3 or less sessions while rest needed 4–6 sessions of sclerotherapy for desired response. The response was excellent in 22 patients while 5 patients showed good response. Eleven patients developed minor side effects in form of fever, local infection, intracystic bleed, and local skin discoloration. Postsclerotherapy, surgery was performed in two patients. CONCLUSION: The better response in the present study can be attributed to targeting of individual cysts in multiloculated lesion, ultrasound-guided aspiration of the cysts content before drug delivery, and postprocedure compression which increases the contact time between cyst wall and bleomycin reducing the chances of postprocedure seroma formation. Since the drug acts on the endothelial lining of the cyst, volume of the cyst is the major determinant in response. Aqueous bleomycin had comparable results with oil-based microsphere establishing it as an economical alternative treatment modality.
format Online
Article
Text
id pubmed-5773987
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-57739872018-01-31 Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult Bhatnagar, Ankur Upadhyaya, Vijai Datta Kumar, Basant Neyaz, Zafar Kushwaha, Ajay Natl J Maxillofac Surg Original Article OBJECTIVES: Lymphatic malformations (LMs) are aberrant proliferation of sequestrated lymphatic vessels during early embryogenesis and do not communicate directly with the general lymphatic system. The absence of vascular flow is the hallmark of LMs and is usually symptomless apart from painless disfiguring mass with concerns regarding cosmesis. DESIGN: Sclerotherapy has gained prominence as a preferred treatment modality for macrocystic lesions. Here, we present our experience with use of aqueous bleomycin as intralesional sclerosing agent, an economical first-line treatment for macrocystic variant of LMs in children and adults. While bleomycin microsphere in oil has been commonly used in many previous studies, we have used aqueous bleomycin solution as the sclerosing modality which is easily available and economical. MATERIALS AND METHODS: Twenty-seven patients of macrocystic LM including adults and children underwent bleomycin sclerotherapy under ultrasonography guidance. Number of sessions, dose administered, and the response to therapy along with all side effects were noted. RESULTS: Sixteen patients received 3 or less sessions while rest needed 4–6 sessions of sclerotherapy for desired response. The response was excellent in 22 patients while 5 patients showed good response. Eleven patients developed minor side effects in form of fever, local infection, intracystic bleed, and local skin discoloration. Postsclerotherapy, surgery was performed in two patients. CONCLUSION: The better response in the present study can be attributed to targeting of individual cysts in multiloculated lesion, ultrasound-guided aspiration of the cysts content before drug delivery, and postprocedure compression which increases the contact time between cyst wall and bleomycin reducing the chances of postprocedure seroma formation. Since the drug acts on the endothelial lining of the cyst, volume of the cyst is the major determinant in response. Aqueous bleomycin had comparable results with oil-based microsphere establishing it as an economical alternative treatment modality. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5773987/ /pubmed/29386816 http://dx.doi.org/10.4103/njms.NJMS_6_17 Text en Copyright: © 2017 National Journal of Maxillofacial Surgery http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Bhatnagar, Ankur
Upadhyaya, Vijai Datta
Kumar, Basant
Neyaz, Zafar
Kushwaha, Ajay
Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult
title Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult
title_full Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult
title_fullStr Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult
title_full_unstemmed Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult
title_short Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult
title_sort aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: our experience with children and adult
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773987/
https://www.ncbi.nlm.nih.gov/pubmed/29386816
http://dx.doi.org/10.4103/njms.NJMS_6_17
work_keys_str_mv AT bhatnagarankur aqueousintralesionalbleomycinsclerotherapyinlymphaticmalformationourexperiencewithchildrenandadult
AT upadhyayavijaidatta aqueousintralesionalbleomycinsclerotherapyinlymphaticmalformationourexperiencewithchildrenandadult
AT kumarbasant aqueousintralesionalbleomycinsclerotherapyinlymphaticmalformationourexperiencewithchildrenandadult
AT neyazzafar aqueousintralesionalbleomycinsclerotherapyinlymphaticmalformationourexperiencewithchildrenandadult
AT kushwahaajay aqueousintralesionalbleomycinsclerotherapyinlymphaticmalformationourexperiencewithchildrenandadult